Zerintia HealthTech Focuses on Saudi Arabia and the United Arab Emirates

Zerintia HealthTech is focusing on the Middle East. The Spanish company specialising in digital health, a spin-off of Zerintia Technologies, has reached an agreement with local partners in the region to begin operating its technological solutions in Saudi Arabia and the United Arab Emirates.

Medical device and equipment provider El-Ajou has been selected to operate with Zerintia HealthTech in Saudi Arabia, while in the United Arab Emirates, the Spanish company has partnered with healthcare solutions company Emitac Healthcare Solutions.

Specifically, Zerintia HealthTech will begin operating in both countries with its 4RemoteHealth platform, which enables collaboration between medical professionals in real time remotely, sharing the different signals from existing clinical devices, as well as voice, image and video, in different highly complex clinical environments. Through it, the world’s first remote-assisted surgery with 5G has been possible.

Zerintia HealthTech will develop its 4RemoteHealth platform in both Middle East territories

This is an IoT SaaS platform with which Zerintia HealthTech seeks to become the reference partner in digital health for healthcare professionals and institutions around the world.

The Spanish company’s international expansion coincides with the reorganization that the company carried out this year, after strengthening its board of directors last summer. María Vila, former general manager of Medtronic in Spain and Portugal and former president of the Spanish Federation of Health Technology Companies (Fenin), joined the top management of Zerintia HealthTech in June.

Founded in 2022 as a spin-off of Zerintia Technologies, the company Zerintia HealthTech is one of the Spanish providers of software solutions services that integrate wearable technology ; Internet of Things (IoT); augmented reality; and people.

__

(Featured image by CDC via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us